Intellia Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
27/02/2025 15:07
Intellia Therapeutics Inc NTLA.OQ reported a quarterly adjusted loss of $1.27 per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.46. The mean expectation of twenty five analysts for the quarter was for a loss of $1.33 per share. Wall Street expected results to range from $-1.61 to -86 cents per share. Revenue rose 771.6% to $12.87 million from a year ago; analysts expected $8.53 million. Intellia Therapeutics Inc's reported EPS for the quarter was a loss of $1.27. The company reported a quarterly loss of $128.9 million. Intellia Therapeutics Inc shares had fallen by 7.4% this quarter. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 0.8% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy," 7 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Intellia Therapeutics Inc is $46.00 This summary was machine generated from LSEG data February 27 at 03:07 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -1.33 | -1.27 | Beat |
| Sep. 30 2024 | -1.38 | -1.34 | Beat |
| Jun. 30 2024 | -1.23 | -1.52 | Missed |
| Mar. 31 2024 | -1.38 | -1.12 | Beat |
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)